

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

## Test

Sample	Group	N	Result	N <sub>rel</sub>
--------	-------	---	--------	------------------

## Set 1

## (231) Rheumat. fac. (scr)

A1	(1) Abbott	>>>	36	Positive	21 %
	(12) Beckman Coulter	>>>	7	Positive	4,1 %
	(58) Beckman Coulter (AU)	>>>	22	Positive	13 %
	(60) Roche	>>>	48	Positive	28 %
	(70) Wako	>>>	1	Positive	0,59 %
	(91) Binding Site	>>>	3	Positive	1,8 %
	(115) BioSystems	>>>	3	Positive	1,8 %
	(116) Sentinel Diagnostics		1	Negative	0,59 %
		>>>	2	Positive	1,2 %
	(148) Aesku.lab Diagnostika	>>>	2	Positive	1,2 %
	(149) Siemens (Dade, BN, Dimension)	>>>	11	Positive	6,5 %
	(162) Siemens (Atellica)	>>>	13	Positive	7,6 %
	(177) Mindray	>>>	5	Positive	2,9 %
	(178) DiaSys	>>>	3	Positive	1,8 %
	(179) Siemens	>>>	12	Positive	7,1 %
	(999) another manufacturer	>>>	1	Positive	0,59 %
Total per sample: n = 170		Success: 99 %			

B1	(1) Abbott	>>>	36	Negative	21 %
	(12) Beckman Coulter	>>>	7	Negative	4,1 %
	(58) Beckman Coulter (AU)	>>>	22	Negative	13 %
	(60) Roche	>>>	48	Negative	28 %
	(70) Wako	>>>	1	Negative	0,59 %
	(91) Binding Site	>>>	3	Negative	1,8 %
	(115) BioSystems	>>>	3	Negative	1,8 %
	(116) Sentinel Diagnostics	>>>	3	Negative	1,8 %
	(148) Aesku.lab Diagnostika	>>>	2	Negative	1,2 %
	(149) Siemens (Dade, BN, Dimension)	>>>	11	Negative	6,5 %
	(162) Siemens (Atellica)	>>>	13	Negative	7,6 %
	(177) Mindray	>>>	5	Negative	2,9 %
	(178) DiaSys	>>>	3	Negative	1,8 %
	(179) Siemens	>>>	12	Negative	7,1 %
	(999) another manufacturer	>>>	1	Negative	0,59 %
Total per sample: n = 170		Success: 100 %			

Total success: 99 %

## (233) Rheumat. factor IgG

A1	(1) Abbott	>>>	1	Positive	2,1 %
	(5) Dialab	>>>	1	Positive	2,1 %
	(58) Beckman Coulter (AU)	>>>	1	Positive	2,1 %
	(135) OrgenTec	>>>	11	Positive	23 %
	(140) TestLine	>>>	20	Positive	42 %
	(147) AIDA	>>>	3	Positive	6,3 %
	(148) Aesku.lab Diagnostika	>>>	4	Positive	8,3 %
	(166) Thermo Fisher	>>>	6	Positive	13 %
	(211) INOVA Diagnostics	>>>	1	Positive	2,1 %
Total per sample: n = 48		Success: 100 %			

B1	(1) Abbott	>>>	1	Negative	2,1 %
	(5) Dialab	>>>	1	Negative	2,1 %
	(58) Beckman Coulter (AU)	>>>	1	Negative	2,1 %
	(135) OrgenTec	>>>	10	Negative	21 %
			1	Inconclusive result (borderline)	2,1 %
	(140) TestLine	>>>	20	Negative	42 %
	(147) AIDA	>>>	3	Negative	6,3 %
	(148) Aesku.lab Diagnostika	>>>	4	Negative	8,3 %
	(166) Thermo Fisher	>>>	6	Negative	13 %
	(211) INOVA Diagnostics	>>>	1	Negative	2,1 %
Total per sample: n = 48		Success: 98 %			

Total success: 98 %

## (234) Rheumat. factor IgA

A1	(5) Dialab	>>>	1	Positive	2,2 %
	(135) OrgenTec	>>>	11	Positive	24 %
	(140) TestLine	>>>	20	Positive	43 %
	(147) AIDA	>>>	3	Positive	6,5 %

## Summary statistics - qualitative results

(Groups: manufacturer of kit)

## EQA round: RF2/22 - Diagnostics of Rheumatoid Arthritis and ASLO

Deadline: 30.09.2022

Test	Sample	Group	N	Result	N <sub>rel</sub>
A1	(148)	Aesku.lab Diagnostika	>>>	4 Positive	8,7 %
	(166)	Thermo Fisher	>>>	6 Positive	13 %
	(211)	INOVA Diagnostics	>>>	1 Positive	2,2 %
	Total per sample: n = 46		Success: 100 %		
B1	(5)	Dialab	>>>	1 Negative	2,2 %
	(135)	OrgenTec	>>>	11 Negative	24 %
	(140)	TestLine	>>>	20 Negative	43 %
	(147)	AIDA	>>>	3 Negative	6,5 %
	(148)	Aesku.lab Diagnostika	>>>	4 Negative	8,7 %
	(166)	Thermo Fisher	>>>	6 Negative	13 %
	(211)	INOVA Diagnostics	>>>	1 Negative	2,2 %
Total per sample: n = 46		Success: 100 %			
Total success: 100 %					

**(235) Rheumat. factor IgM**

A1	(5)	Dialab	>>>	1 Positive	2,2 %
	(135)	OrgenTec	>>>	11 Positive	24 %
	(140)	TestLine	>>>	20 Positive	43 %
	(147)	AIDA	>>>	3 Positive	6,5 %
	(148)	Aesku.lab Diagnostika	>>>	4 Positive	8,7 %
	(166)	Thermo Fisher	>>>	6 Positive	13 %
	(211)	INOVA Diagnostics	>>>	1 Positive	2,2 %
Total per sample: n = 46		Success: 100 %			
B1	(5)	Dialab	>>>	1 Negative	2,2 %
	(135)	OrgenTec	>>>	11 Negative	24 %
	(140)	TestLine	>>>	20 Negative	43 %
	(147)	AIDA	>>>	3 Negative	6,5 %
	(148)	Aesku.lab Diagnostika	>>>	4 Negative	8,7 %
	(166)	Thermo Fisher	>>>	6 Negative	13 %
	(211)	INOVA Diagnostics	>>>	1 Negative	2,2 %
Total per sample: n = 46		Success: 100 %			
Total success: 100 %					

**(277) anti-CCP IgG**

A1	(1)	Abbott	>>>	20 Positive	24 %
	(14)	Bio-Rad	>>>	1 Positive	1,2 %
	(29)	Siemens (Immulin)	>>>	6 Positive	7,3 %
	(60)	Roche	>>>	10 Positive	12 %
	(66)	DRG	>>>	1 Positive	1,2 %
	(87)	Euroimmun	>>>	9 Positive	11 %
	(135)	OrgenTec	>>>	4 Positive	4,9 %
	(140)	TestLine	>>>	9 Positive	11 %
	(147)	AIDA	>>>	1 Positive	1,2 %
	(148)	Aesku.lab Diagnostika	>>>	2 Positive	2,4 %
	(162)	Siemens (Atellica)	>>>	3 Positive	3,7 %
	(166)	Thermo Fisher	>>>	7 Positive	8,5 %
	(179)	Siemens	>>>	2 Positive	2,4 %
	(211)	INOVA Diagnostics	>>>	5 Positive	6,1 %
	(999)	another manufacturer	>>>	2 Positive	2,4 %
Total per sample: n = 82		Success: 100 %			
B1	(1)	Abbott	>>>	20 Negative	24 %
	(14)	Bio-Rad	>>>	1 Negative	1,2 %
	(29)	Siemens (Immulin)	>>>	6 Negative	7,3 %
	(60)	Roche	>>>	10 Negative	12 %
	(66)	DRG	>>>	1 Negative	1,2 %
	(87)	Euroimmun	>>>	9 Negative	11 %
	(135)	OrgenTec	>>>	4 Negative	4,9 %
	(140)	TestLine	>>>	9 Negative	11 %
	(147)	AIDA	>>>	1 Negative	1,2 %
	(148)	Aesku.lab Diagnostika	>>>	2 Negative	2,4 %
	(162)	Siemens (Atellica)	>>>	3 Negative	3,7 %
	(166)	Thermo Fisher	>>>	7 Negative	8,5 %
	(179)	Siemens	>>>	2 Negative	2,4 %
	(211)	INOVA Diagnostics	>>>	5 Negative	6,1 %
	(999)	another manufacturer	>>>	2 Negative	2,4 %
Total per sample: n = 82		Success: 100 %			
Total success: 100 %					

**(282) anti-MCV**

A1	(135)	OrgenTec	>>>	22 Positive	96 %
----	-------	----------	-----	-------------	------

**Summary statistics - qualitative results**

(Groups: manufacturer of kit)

**EQA round: RF2/22 - Diagnostics of Rheumatoid Arthritis and ASLO**

Deadline: 30.09.2022

**Test**

Sample	Group	N	Result	N <sub>rel</sub>
A1	(166) Thermo Fisher	>>> 1	Positive	4,3 %
----- Total per sample: n = 23 -----		Success: 100 %		
B1	(135) OrgenTec	>>> 22	Negative	96 %
	(166) Thermo Fisher	>>> 1	Negative	4,3 %
----- Total per sample: n = 23 -----		Success: 100 %		
Total success: 100 %				

st\_kl

End of report

Printed: 07.10.2022